- Medifast press release ( NYSE: MED ): Q2 Non-GAAP EPS of $3.87 beats by $0.64 .
- Revenue of $453.3M (+15.0% Y/Y) beats by $5.43M .
- The company expects full-year 2022 revenue to be in the range of $1.58 billion to $1.66 billion (vs. consensus of $1.81B), down from the previously announced range of $1.78 billion to $1.84 billion.
- The company expects full-year 2022 non-GAAP diluted EPS to be in the range of $12.70 to $14.10 (vs. consensus of $15.38), down from the previously announced range of $14.60 to $16.05.
- The decline in the company's outlook is due to macroeconomic factors such as inflation and consumer sentiment which have impacted customer retention.
- The revised full-year 2022 earnings guidance assumes a 24.25% to 25.25% effective tax rate.
For further details see:
Medifast reports Q2 earnings beat; narrows FY22 guidance